Reference : Hearing Preservation in Cochlear Implantation and Drug Treatment.
Scientific journals : Article
Human health sciences : Otolaryngology
Human health sciences : Neurology
Hearing Preservation in Cochlear Implantation and Drug Treatment.
Barriat, Sébastien mailto [Centre Hospitalier Universitaire de Liège - CHU > > O.R.L. >]
Poirrier, Anne-Lise [Centre Hospitalier Universitaire de Liège - CHU > > O.R.L. >]
Malgrange, Brigitte mailto [Université de Liège - ULiège > > GIGA - Neurosciences - Neurologie >]
Lefèbvre, Philippe mailto [Université de Liège - ULiège > Département des sciences cliniques > Oto-rhino-laryngologie et audiophonologie >]
Advances in Oto-Rhino-Laryngology
Yes (verified by ORBi)
[en] Insertion of an electrode array into the cochlea produces immediate damage to the inner ear, which is responsible for a hearing loss. In addition, a delayed hearing loss can be observed. In order to maximize hearing preservation after insertion of an electrode and to enhance the performance of the cochlear implant, it has been proposed to deliver pharmacological agents to the inner ear. Molecules can be administered locally to the inner ear through a direct perilymphatic perfusion or through the round window membrane. These modalities of treatment have already been successfully applied to some patients with inner ear diseases. In this paper, we will review some basic aspects of drug delivery to the inner ear to prevent the degeneration of the neurosensory hair cells and auditory neurons, and the actual applicability to humans in order to maintain hearing function after the insertion of electrodes of a cochlear implant.
Copyright (c) 2010 S. Karger AG, Basel.

File(s) associated to this reference

Fulltext file(s):

Restricted access
barriat_2010_adv_oto.htmPublisher postprint19.03 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.